DCM
ABCL icon

Driehaus Capital Management’s AbCellera Biologics ABCL Stock Holding History

Driehaus Capital Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14M Buy
4,024,779
+252,780
+7% +$910K 0.1% 247
2025
Q4 		$12.9M Buy
3,771,999
+2,045,058
+118% +$9.13M 0.09% 262
2025
Q3 		$8.69M Buy
1,726,941
+1,227,019
+245% +$5.41M 0.06% 290
2025
Q2 		$1.71M Buy
+499,922
New +$1.24M 0.01% 338

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Driehaus Capital Management's ABCL Position: Q1 2026 in Review

Driehaus Capital Management increased its AbCellera Biologics (ABCL) stake by 6.7% in Q1 2026, buying an estimated $910K and bringing the position to 4,024,779 shares worth $14M. The position accounts for 0.1% of the portfolio, ranked #247.

Driehaus Capital Management first reported a position in ABCL in Q2 2025 and has held it in 4 quarters since. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

  • Driehaus Capital Management held 4,024,779 shares of AbCellera Biologics worth $14M as of Q1 2026.
  • Driehaus Capital Management bought 252,780 AbCellera Biologics shares in Q1 2026, an estimated $910K.
  • AbCellera Biologics made up 0.1% of Driehaus Capital Management's portfolio in Q1 2026, its #247 holding.
  • Driehaus Capital Management first reported a position in AbCellera Biologics in Q2 2025 and has held it in 4 quarters since.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.